Clinical trials: EOS
Asthma
Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma
This study will evaluate two dose regimens of mepolizumab [75mg intravenous (i.v.) or 100mg subcutaneous (SC) every 4 weeks] compared with placebo over a 32 week treatment period in subjects with severe refractory asthma with…
- Trial name
- NCT01691521
- Testing
- Mepolizumab IV, Mepolizumab SC
- Where
- 134 sites in United States, Argentina and 14 more
- Volunteers
- 580 people
- Sponsor
- GlaxoSmithKline
Asthma
Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma
The purpose of this study is to show whether mepolizumab given every 4 weeks intravenously (i.v.) can reduce the frequency of asthma exacerbations in subjects with severe asthma despite receiving high doses of standard asthma…
- Trial name
- DREAM (NCT01000506)
- Testing
- Mepolizumab 750, Mepolizumab 250, Mepolizumab 75
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 621 people
- Sponsor
- GlaxoSmithKline
Eosinophilic Esophagitis
A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
Study CC-93538-EE-001 is a Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled induction and maintenance study to evaluate the efficacy and safety of CC- 93538 in adult and adolescent participants…
- Trial name
- NCT04753697
- Testing
- CC-93538
- Where
- 212 sites in United States, Argentina and 13 more
- Volunteers
- 430 people
- Sponsor
- Celgene
Asthma
A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects
This is a multi-center, open-label, long-term study of subcutaneously (SC) administered mepolizumab 100mg in addition to standard of care (SOC), in subjects with severe eosinophilic asthma.
- Trial name
- NCT02135692
- Testing
- Mepolizumab, SOC
- Where
- 114 sites in United States, Argentina and 16 more
- Volunteers
- 339 people
- Sponsor
- GlaxoSmithKline
Eosinophilic Esophagitis
Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
This study is an open-label, uncontrolled study design to evaluate the long-term safety and tolerability of treatment with CC-93538.
- Trial name
- NCT04991935
- Testing
- CC-93538
- Where
- 167 sites in United States, Argentina and 13 more
- Volunteers
- 367 people
- Sponsor
- Celgene
Eosinophils, Asthma
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
This is a multicenter, open-label (OL) extension study to obtain additional long-term safety data for subcutaneous (sc) administration of reslizumab treatment administered at a fixed dose of 110 mg in patients 12 years of age and…
- Trial name
- NCT03052725
- Testing
- reslizumab
- Where
- 134 sites in United States, Belgium and 11 more
- Volunteers
- 391 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects
This is a multi-centre, open-label long-term safety study of 100 milligram (mg) mepolizumab administered subcutaneously (SC) every 4 weeks for 12 months in addition to standard of care in subjects who have severe, refractory…
- Trial name
- NCT01842607
- Testing
- Mepolizumab
- Where
- 137 sites in United States, Argentina and 17 more
- Volunteers
- 651 people
- Sponsor
- GlaxoSmithKline
Asthma
Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma
This is a randomised, double-blind, placebo-controlled, parallel-group, multicenter study of mepolizumab in comparison with placebo in reducing Oral Corticosteroid (OCS) use in subjects with severe refractory asthma.
- Trial name
- NCT01691508
- Testing
- Mepolizumab, OCS (prednisone/prednisolone)
- Where
- 47 sites in United States, Australia and 8 more
- Volunteers
- 135 people
- Sponsor
- GlaxoSmithKline
Eosinophilic Esophagitis
A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis
This is a Phase 2/3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lirentelimab (AK002) given monthly for 6 doses in adult and adolescent patients with active eosinophilic…
- Trial name
- KRYPTOS (NCT04322708)
- Testing
- lirentelimab (AK002)
- Where
- 78 sites in United States, Australia and 1 more
- Volunteers
- 277 people
- Sponsor
- Allakos Inc.
Asthma
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
This study is researching a drug called dupilumab. The study is focused on patients who have uncontrolled asthma. Asthma is a condition where the airways narrow and swell, making it difficult to breathe.
- Trial name
- AIM4:Next Step (NCT06572228)
- Testing
- dupilumab, ICS/LABA
- Where
- 77 sites in United States, Canada and 4 more
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
Asthma, Elevated Blood Eosinophils
An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils
The primary objective of the study is to determine the ability of reslizumab administered by subcutaneous injection to produce a corticosteroid-sparing effect in patients with oral corticosteroid (OCS)-dependent asthma and…
- Conditions
- Asthma, Elevated Blood Eosinophils, Oral Corticosteroid Dependence
- Trial name
- NCT02501629
- Testing
- Reslizumab, Non-Oral Corticosteroid (non-OCS) Asthma Medication, Oral Corticosteroid (OCS)
- Where
- 127 sites in United States, Argentina and 15 more
- Volunteers
- 177 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Scoliosis, Scoliosis Idiopathic
Minimal Invasive Deformity Correction (MID-C) System for Early Onset Scoliosis
Early Onset Scoliosis (EOS) is defined as scoliosis with onset under the age of ten years, regardless of etiology. It is a complex three-dimensional deformity of the spine which can cause significant physical and psychological…
- Conditions
- Scoliosis, Scoliosis Idiopathic, Scoliosis;Congenital
- Trial name
- NCT03519321
- Testing
- MID-C
- Where
- Greece
- Volunteers
- 60 people
- Sponsor
- Apifix
Asthma
Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States
To asses effectiveness and safety of tezepelumab in adult and adolescent participants with severe asthma including several under-studied populations in the United States.
- Trial name
- PASSAGE (NCT05329194)
- Testing
- Tezepelumab
- Where
- 37 sites in United States
- Volunteers
- 286 people
- Sponsor
- AstraZeneca
Asthma
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
The primary objective of this study is to determine the effect of reslizumab (110 mg) administered subcutaneously every 4 weeks on clinical asthma exacerbations in adults and adolescents with asthma and elevated blood eosinophils…
- Trial name
- NCT02452190
- Testing
- Reslizumab
- Where
- 226 sites in United States, Argentina and 19 more
- Volunteers
- 468 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.